|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013216,
umls-concept:C0023484,
umls-concept:C0038250,
umls-concept:C0206152,
umls-concept:C0229664,
umls-concept:C0242596,
umls-concept:C0439859,
umls-concept:C0580822,
umls-concept:C0677874,
umls-concept:C1521991,
umls-concept:C1522577,
umls-concept:C1547300,
umls-concept:C1548760,
umls-concept:C1550594
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
1999-2-10
|
|
pubmed:abstractText |
Plasma cell leukemia is a rare disease associated with very poor survival with standard treatment. We report a patient affected by plasma cell leukemia treated with aggressive chemotherapy and autologous CD34-selected PBPC who achieved a complete remission now lasting more than 2 years. Molecular studies confirmed the presence of minimal residual disease (MRD) despite the absence of disease activity. High-dose chemotherapy with stem cell rescue may be applied to selected patients considering the impact of the treatment on survival. The meaning of molecular MRD in this setting is unclear.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0268-3369
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
823-5
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9827984-Antigens, CD34,
pubmed-meshheading:9827984-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9827984-Combined Modality Therapy,
pubmed-meshheading:9827984-Female,
pubmed-meshheading:9827984-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:9827984-Humans,
pubmed-meshheading:9827984-Leukemia, Plasma Cell,
pubmed-meshheading:9827984-Middle Aged,
pubmed-meshheading:9827984-Neoplasm, Residual,
pubmed-meshheading:9827984-Remission Induction,
pubmed-meshheading:9827984-Time Factors,
pubmed-meshheading:9827984-Transplantation, Autologous
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Long-lasting complete remission in plasma cell leukemia after aggressive chemotherapy and CD34-selected autologous peripheral blood progenitor cell transplant: molecular follow-up of minimal residual disease.
|
|
pubmed:affiliation |
Istituto di Semeiotica Medica, Divisione di Ematologia, Università Cattolica Sacro Cuore, Roma, Italy.
|
|
pubmed:publicationType |
Journal Article,
Case Reports,
Research Support, Non-U.S. Gov't
|
